2020 has been a challenging year for all of us. We have experienced firsthand how a global pandemic has changed the world we live in. In spite of this, we’ve seen people and business coming together to make a difference. CPC Scientific’s mission is to collaborate with our customers to improve the quality of […]
SAN JOSE, CA., Sept 3, 2020 /CPCNewswire/ — CPC Scientific Inc. is pleased to announce that the European Commission (EC) has granted the Conditional Marketing Authorization (CMA) for MYR Pharmaceuticals lead compound HEPCLUDEX®. CPC Scientific serves as a supplier and partner to MYR Pharmaceuticals for the development and manufacturing of bulevirtide (Hepcludex). This drug is […]
SAN JOSE, CA., June 25, 2020 /CPCNewswire/ — CPC Scientific Inc., a San Jose based CDMO with GMP manufacturing facilities in Hangzhou, is pleased to announce that their drug master file (DMF) for cetrorelix acetate has been submitted to the U.S. Food and Drug Administration and has been issued DMF# 034884. This generic peptide API […]
We are very excited about the addition of the cetrorelix DMF to our growing generic peptide portfolio. Our multi-kg scale cGMP manufacturing facility for cetrorelix will provide more opportunities for IVF treatments in the medical communities and pathways to new treatments for hormone-sensitive breast and prostate cancers.
On 28 May 2020, the European Medicines Agency (EMA), via its Committee for Medicinal Products for Human Use (CHMP), adopted a positive opinion of Hepcludex. This drug is intended for the treatment of chronic hepatitis delta virus (HDV) infection in adult patients with compensated liver disease, and effectively reduces HDV RNA levels and signs of […]
To Our Valued Customers,
With the growing concern of the Coronavirus Disease 2019 (COVID-19) outbreak, CPC Scientific wants to assure you that our peptide manufacturing facilities are fully operational and staffed. We continue to deliver our GMP- and research-grade peptides on time to the researchers and pharmaceutical companies who rely on our products. The safety of […]
San Jose, CA and New York, NY – CPC Scientific Inc., a CDMO specializing in synthetic peptide manufacturing, will host at DCAT Week® for a 5th consecutive year. Their representatives will be open for meetings during March 23-26th at:
Omni Berkshire Place #1632
21 East 52nd St.
New York, NY 10022Appointments requests may be requested at the CPC […]
SUNNYVALE, US. and Hangzhou, China, June 24th, 2019 /CPCNewswire/ — CPC Scientific Inc. and its affiliate Chinese Peptide Company, a public Hangzhou-based CDMO (Stock Symbol: 002390) is pleased to announce today that their GMP manufacturing facility, has successfully passed its inspection by the competent authority of Germany as an“active substance manufacturer that has been inspected […]
to Manufacture Neoantigen Peptides for the PANDA (Personalized and Adaptive) Cancer Vaccine Program.
SUNNYVALE, California, Feb. 19, 2019 – CPC Scientific Inc., a leading global CDMO specializing in synthetic peptide manufacturing, announced today that they will manufacture GMP-grade neoantigen peptides for investigators at UNC Lineberger Comprehesive Cancer Center (LCCC) for the purpose of individualized immunotherapy. CPC […]
This year, “The 7th CPC Symposium on Peptide Therapeutics” will continue the tradition of the successful conferences from previous years. The meeting will offer a forum for scientific discussions of recent developments in the exciting field of peptide therapeutics. It will feature lectures on a broad range of topics including new technologies, drug discovery, CMC, […]
HANGZHOU, CHINA – March 17, 2016 – CPC Scientific Inc. is pleased to announce that the CPC Scientific Inc. Good Manufacturing Practice (GMP) facility in Hangzhou, China has successfully passed its fourth U.S. Food and Drug Administration (FDA) inspection. No Form 483 observations were issued.
Passing this inspection is an important milestone for CPC Scientific Inc. […]
